These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 16690052

  • 1. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
    Okumura T, Murata Y, Hizue M, Matsuura T, Naganeo R, Kanai Y, Murase A, Sakakibara A, Fujita I, Nakao K.
    Eur J Pharmacol; 2006 Jun 06; 539(1-2):125-30. PubMed ID: 16690052
    [Abstract] [Full Text] [Related]

  • 2. Mathematical analysis of involvement ratio between central and peripheral COX-2 in rat pain models with two types of COX-2 inhibitors with different distribution, celecoxib and CIAA.
    Okumura T, Sakakibara A, Murata Y, Kita Y.
    Eur J Pharmacol; 2008 Jan 06; 578(1):97-9. PubMed ID: 17716650
    [Abstract] [Full Text] [Related]

  • 3. Discovery of a novel COX-2 inhibitor as an orally potent anti-pyretic and anti-inflammatory drug: design, synthesis, and structure-activity relationship.
    Hayashi S, Sumi Y, Ueno N, Murase A, Takada J.
    Biochem Pharmacol; 2011 Oct 01; 82(7):755-68. PubMed ID: 21741371
    [Abstract] [Full Text] [Related]

  • 4. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug 01; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
    Yoshino T, Kimoto A, Kobayashi S, Noguchi M, Fukunaga M, Hayashi A, Miyata K, Sasamata M.
    Arzneimittelforschung; 2005 Aug 01; 55(7):394-402. PubMed ID: 16080279
    [Abstract] [Full Text] [Related]

  • 6. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2.
    King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, Marshall PJ, O'Byrne L, Quadros E, Toutain PL, Lees P.
    J Vet Pharmacol Ther; 2009 Feb 01; 32(1):1-17. PubMed ID: 19161451
    [Abstract] [Full Text] [Related]

  • 7. ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
    Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL.
    J Pharmacol Exp Ther; 2004 Dec 01; 311(3):904-12. PubMed ID: 15277581
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and anti-inflammatory evaluation of a series of novel amino acid-binding 1,5-diarylpyrazole derivatives.
    Li MH, Yin LL, Cai MJ, Zhang WY, Huang Y, Wang X, Zhu XZ, Shen JK.
    Acta Pharmacol Sin; 2005 Jul 01; 26(7):865-72. PubMed ID: 15960895
    [Abstract] [Full Text] [Related]

  • 9. Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
    Navidpour L, Amini M, Shafaroodi H, Abdi K, Ghahremani MH, Dehpour AR, Shafiee A.
    Bioorg Med Chem Lett; 2006 Sep 01; 16(17):4483-7. PubMed ID: 16806914
    [Abstract] [Full Text] [Related]

  • 10. Specific roles of cyclooxygenase-1 and cyclooxygenase-2 in lipopolysaccharide-induced fever and Fos expression in rat brain.
    Zhang YH, Lu J, Elmquist JK, Saper CB.
    J Comp Neurol; 2003 Aug 11; 463(1):3-12. PubMed ID: 12811798
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of 2 celecoxib derivatives: analgesic effect and selectivity to cyclooxygenase-2/1.
    Lu ZH, Xiong XY, Zhang BL, Lin GC, Shi YX, Liu ZG, Meng JR, Zhou YM, Mei QB.
    Acta Pharmacol Sin; 2005 Dec 11; 26(12):1505-11. PubMed ID: 16297351
    [Abstract] [Full Text] [Related]

  • 12. Anti-inflammatory effects of selective COX-2 inhibitors.
    Süleyman H, Demircan B, Karagöz Y, Oztaşan N, Süleyman B.
    Pol J Pharmacol; 2004 Dec 11; 56(6):775-80. PubMed ID: 15662090
    [Abstract] [Full Text] [Related]

  • 13. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, Cordon-Cardo C, Thaler HT, Dannenberg AJ.
    Clin Cancer Res; 2005 Mar 01; 11(5):1999-2007. PubMed ID: 15756026
    [Abstract] [Full Text] [Related]

  • 14. Covalent binding of radioactivity from [14C]rofecoxib, but not [14C]celecoxib or [14C]CS-706, to the arterial elastin of rats.
    Oitate M, Hirota T, Koyama K, Inoue S, Kawai K, Ikeda T.
    Drug Metab Dispos; 2006 Aug 01; 34(8):1417-22. PubMed ID: 16679386
    [Abstract] [Full Text] [Related]

  • 15. The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production.
    Skarke C, Reus M, Schmidt R, Grundei I, Schuss P, Geisslinger G, Lötsch J.
    Clin Pharmacol Ther; 2006 Dec 01; 80(6):621-32. PubMed ID: 17178263
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
    Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S.
    Biochem Pharmacol; 2011 Oct 01; 82(7):746-54. PubMed ID: 21745460
    [Abstract] [Full Text] [Related]

  • 17. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain.
    Guo JY, Li CY, Ruan YP, Sun M, Qi XL, Zhao BS, Luo F.
    Eur J Pharmacol; 2009 Jun 10; 612(1-3):54-60. PubMed ID: 19356723
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors.
    Gierse J, Nickols M, Leahy K, Warner J, Zhang Y, Cortes-Burgos L, Carter J, Seibert K, Masferrer J.
    Eur J Pharmacol; 2008 Jun 24; 588(1):93-8. PubMed ID: 18457826
    [Abstract] [Full Text] [Related]

  • 19. Endogenous opioids mediate the hypoalgesia induced by selective inhibitors of cyclo-oxygenase 2 in rat paws treated with carrageenan.
    França DS, Ferreira-Alves DL, Duarte ID, Ribeiro MC, Rezende RM, Bakhle YS, Francischi JN.
    Neuropharmacology; 2006 Jul 24; 51(1):37-43. PubMed ID: 16620880
    [Abstract] [Full Text] [Related]

  • 20. Involvement of cyclooxygenase-2 in rat models of conjunctivitis.
    Oka T, Shearer T, Azuma M.
    Curr Eye Res; 2004 Jul 24; 29(1):27-34. PubMed ID: 15370364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.